CXCL10 and sarcopenia: In addition, in this study, among the group with high baseline IP-10 levels or high 1-year ratios, patients who had undergone TACE more than twice during the follow-up period developed sarcopenia more frequently than those who had undergone TACE less than twice (86 vs. 50%, p = 0.006).